BRAF Status in Papillary Microcarcinomas of the Thyroid Gland: a Brief Review-Reference-Cited by-同舟云学术

BRAF Status in Papillary Microcarcinomas of the Thyroid Gland: a Brief Review

Published:2019-10-11 Issue:9 Volume:19 Page:665-672
ISSN:1566-5240
Container-title:Current Molecular Medicine
language:en
Short-container-title:CMM

Author:

Ieni Antonio¹,Vita Roberto²,Cardia Roberta¹,Giuffré Giuseppe¹,Benvenga Salvatore²,Tuccari Giovanni¹

Affiliation:

1. Department of Human Pathology "Gaetano Barresi" - Section of Pathological Anatomy, A.O.U. Polyclinic G.Martino, 98125 Messina, Italy

2. Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy

Abstract

: Papillary thyroid microcarcinoma (PTMC) is defined by the World Health Organization as papillary cancer measuring 10 mm or less in diameter. Generally, PTMC shows an indolent clinical behavior with a good prognosis, although a minority of PTMC is characterized by an aggressive course. However, efforts to identify this aggressive subset of PTMC after surgery remain inconclusive. : Several oncogenic pathways have been identified in thyroid cancer and have been applied translationally to improve prognosis and clinical management. In particular, the BRAFV600E mutation was found more frequently in large, aggressive, recurrent and advanced tumors. : We aimed at reviewing studies on BRAFV600E mutation as a prognostic factor in PTMC.

Publisher

Bentham Science Publishers Ltd.

Subject

Molecular Biology,Molecular Medicine,General Medicine,Biochemistry

Reference98 articles.

1. Salamanca-Fernández E.; Rodriguez-Barranco M.; Chang-Chan Y.L.; Thyroid Cancer Epidemiology in South Spain: a population-based time trend study. Endocrine 2018,62(2),423-431

2. Ieni A.; Barresi V.; Cardia R.; The micropapillary/hobnail variant of papillary thyroid carcinoma: A review of series described in the literature compared to a series from one southern Italy pathology institution. Rev Endocr Metab Disord 2016,17(4),521-527

3. Vita R.; Ieni A.; Tuccari G.; Benvenga S.; The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma. Rev Endocr Metab Disord 2018,19(4),301-309

4. Ieni A.; Vita R.; Magliolo E.; One-third of an archivial series of papillary thyroid cancer (Years 2007-2015) has coexistent chronic lymphocytic thyroiditis, which is associated with a more favorable tumor-node-metastasis staging. Front Endocrinol (Lausanne) 2017,8,337

5. Vigneri R.; Malandrino P.; Vigneri P.; The changing epidemiology of thyroid cancer: why is incidence increasing? Curr Opin Oncol 2015,27(1),1-7

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thirty years of active surveillance for low-risk thyroid cancer, lessons learned and future directions;Reviews in Endocrine and Metabolic Disorders;2023-10-14

2. Conservative management of low-risk papillary thyroid carcinoma: a review of the active surveillance experience;Thyroid Research;2023-03-13

3. Incidental Papillary Microcarcinoma and Papillary Thyroid Carcinoma in Multinodular Goiter;Analytical Cellular Pathology;2023-01-14

4. Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine;Journal of Personalized Medicine;2021-04-23

5. BRAFV600E mutation is associated with increased prevalence of contralateral lymph-node metastases in low and low-to-intermediate risk papillary thyroid cancer;Nuclear Medicine Communications;2021-02-19